Evidence map›Paper›PMID 25384981›Full record

ArticleThe Journal of biological chemistry2014

Activation of 3-phosphoinositide-dependent kinase 1 (PDK1) and serum- and glucocorticoid-induced protein kinase 1 (SGK1) by short-chain sphingolipid C4-ceramide rescues the trafficking defect of ΔF508-cystic fibrosis transmembrane conductance regulator (ΔF508-CFTR).

Hung Caohuy, Qingfeng Yang, Yvonne Eudy, Thien-An Ha, Andrew E Xu, Matthew Glover, Raymond A Frizzell, Catherine Jozwik, Harvey B Pollard

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Epithelial Na+ Channels, Immune Cells, and Salt.Annual review of physiology · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Is PI3K a Villain in Cystic Fibrosis?American journal of respiratory cell and molecular biology · 2020
    Article
  14. Article
  15. Article
  16. SGK1: The Dark Side of PI3K Signaling.Current topics in developmental biology · 2017
    Review
  17. Article
  18. Article
  19. Hallmarks of therapeutic management of the cystic fibrosis functional landscape.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2015
    Review
  20. MicroRNA profiling identifies miR-129-5p as a regulator of EMT in tubular epithelial cells.International journal of clinical and experimental medicine · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Hung CaohuyFrom the Department of Anatomy, Physiology, and Genetics, School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814 and hung.caohuy@usuhs.edu.
Qingfeng YangFrom the Department of Anatomy, Physiology, and Genetics, School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814 and.
Yvonne EudyFrom the Department of Anatomy, Physiology, and Genetics, School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814 and.
Thien-An HaFrom the Department of Anatomy, Physiology, and Genetics, School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814 and.
Andrew E XuFrom the Department of Anatomy, Physiology, and Genetics, School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814 and.
Matthew Gloverthe Department of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15224.
Raymond A Frizzellthe Department of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15224.
Catherine JozwikFrom the Department of Anatomy, Physiology, and Genetics, School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814 and.
Harvey B PollardFrom the Department of Anatomy, Physiology, and Genetics, School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814 and harvey.pollard@usuhs.edu.
Uniformed Services University of the Health Sciences · USUniversity of Pittsburgh · US

Funding

Co-chaperone Actions in CFTR BiogenesisR01DK068196 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GOETZMAN, ERIC S · 2004 to 2024
$5.8M
NHLBI PROTEOMICS INITIATIVE-N01HV28187N01HV028187 · HV · HENRY M. JACKSON FOUNDATION · PI POLLARD, HARVEY BRUCE · 2002 to 2006
–
NHLBI NIH HHS N01 HV028187NHLBI NIH HHS N01-HV-28187NIDDK NIH HHS R01 DK068196NIDDK NIH HHS R01-DK-35051
6 · The paper itself

Abstract

Cystic fibrosis (CF) is due to a folding defect in the CF transmembrane conductance regulator (CFTR) protein. The most common mutation, ΔF508, prevents CFTR from trafficking to the apical plasma membrane. Here we show that activation of the PDK1/SGK1 signaling pathway with C4-ceramide (C4-CER), a non-toxic small molecule, functionally corrects the trafficking defect in both cultured CF cells and primary epithelial cell explants from CF patients. The mechanism of C4-CER action involves a series of mutual autophosphorylation and phosphorylation events between PDK1 and SGK1. Detailed mechanistic studies indicate that C4-CER initially induces autophosphorylation of SGK1 at Ser(422). SGK1[Ser(P)(422)] and C4-CER coincidently bind PDK1 and permit PDK1 to autophosphorylate at Ser(241). Then PDK1[Ser(P)(241)] phosphorylates SGK1[Ser(P)(422)] at Thr(256) to generate fully activated SGK1[Ser(422), Thr(P)(256)]. SGK1[Ser(P)(422),Thr(P)(256)] phosphorylates and inactivates the E3 ubiquitin ligase Nedd4-2. ΔF508-CFTR is thus free to traffic to the plasma membrane. Importantly, C4-CER-mediated activation of both PDK1 and SGK1 is independent of the PI3K/Akt/mammalian target of rapamycin signaling pathway. Physiologically, C4-CER significantly increases maturation and stability of ΔF508-CFTR (t½ ∼10 h), enhances cAMP-activated chloride secretion, and suppresses hypersecretion of interleukin-8 (IL-8). We suggest that candidate drugs for CF directed against the PDK1/SGK1 signaling pathway, such as C4-CER, provide a novel therapeutic strategy for a life-limiting disorder that affects one child, on average, each day.

Indexed as

Cell LineCell MembraneCeramidesCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDrug Evaluation, PreclinicalEndosomal Sorting Complexes Required for TransportEnzyme ActivationHumansImmediate-Early ProteinsInterleukin-8Nedd4 Ubiquitin Protein LigasesPhosphatidylinositol 3-KinasesPhosphorylationProtein Processing, Post-TranslationalProtein Serine-Threonine KinasesCeramidesCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorEndosomal Sorting Complexes Required for TransportImmediate-Early ProteinsInterleukin-8N-butanoylsphingosineNedd4L protein, humanNedd4 protein, humanNedd4 Ubiquitin Protein LigasesPDK1 protein, humanPhosphatidylinositol 3-KinasesProtein Serine-Threonine KinasesPyruvate Dehydrogenase Acetyl-Transferring KinaseSerum-Glucocorticoid Regulated KinasesUbiquitin-Protein LigasesCeramideCystic FibrosisCystic Fibrosis Transmembrane Conductance Regulator (CFTR)InflammationMembrane Trafficking

Identifiers

PMID25384981
PMCPMC4276863
OpenAlexW2074842161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.